Efficacy and Safety of Adjunctive Local Moxifloxacin Delivery in the Treatment of Periodontitis
| Autor: | Karola Prior, Daniela Mross, Martin Zilly, Martina Gravemeier, Gregor J. Petersilka, Thomas Beikler, Julie Yamamoto, Andreas Völp, Thomas Frank Flemmig |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Administration Topical Moxifloxacin Dental Plaque Dentistry Drug resistance Placebo Aggregatibacter actinomycetemcomitans Gastroenterology Root Planing Placebos Scaling and root planing Anti-Infective Agents Internal medicine Drug Resistance Bacterial Periodontal Attachment Loss medicine Bacteroides Humans Periodontal Pocket Gingival Recession Adverse effect Aged Antibacterial agent Periodontitis Aza Compounds business.industry Middle Aged medicine.disease Chronic periodontitis Bacterial Load Treatment Outcome Chronic Periodontitis Quinolines Dental Scaling Periodontics Female Streptococcus intermedius Safety Gingival Hemorrhage business Porphyromonas gingivalis Treponema denticola Fluoroquinolones Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Periodontology. 82:96-105 |
| ISSN: | 1943-3670 0022-3492 |
| DOI: | 10.1902/jop.2010.100124 |
| Popis: | Moxifloxacin exerts excellent antibacterial activity against most putative periodontal pathogens and has been shown to kill bacteria in biofilm and host cells.Patients with chronic periodontitis were randomly assigned to receive a single subgingival application of a 0.125%, 0.4%, or 1.25% moxifloxacin gel or placebo gel immediately after full-mouth scaling and root planing (SRP). Clinical efficacy measurements were assessed in sites with baseline probing depth (PD) of ≥5.4 mm at 6 weeks and 3 months and any adverse events were determined. In addition, putative periodontal pathogens and resistance of subgingival bacteria against moxifloxacin were assessed.Data of 57 patients were included in the statistical analysis. In all treatment groups, the PD decreased from baseline to 3 months, with the greatest reduction seen in patients treated with moxifloxacin 0.4% (1.5 ± 0.6 mm; P = 0.023 compared to placebo), followed by patients receiving moxifloxacin 1.25% (1.2 ± 0.4), moxifloxacin 0.125% (1.1 ± 1.1), and placebo (1.0 ± 0.6). No linear trend for PD reduction with increasing moxifloxacin concentrations was found. Porphyromonas gingivalis showed the greatest reduction in prevalence among the assessed pathogens, without any significant intergroup differences. No correlation or systematic relationship between adverse events, including bacterial resistance against moxifloxacin, and the investigational gels was found.In periodontal pockets with PD of ≥5.4 mm, a single subgingival administration of a 0.4% moxifloxacin gel as an adjunct to SRP may result in additional PD reduction compared to SRP alone. In addition, the investigated moxifloxacin gels seem to be safe. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text